Clear-Cut Medical
Jim joined ClearCut in April 2019 after more than twenty-five years of experience successfully developing and commercializing innovative medical technologies. Prior to joining ClearCut, Jim served as President & CEO of Mardil Medical, a privately funded early-stage developer of an implantable device system platform addressing structural heart disease conditions; President & CEO, SetPoint Medical; VP, marketing & business development at InnerPulse, a privately funded developer of a novel implantable defibrillator system; and VP, marketing & business development at Closure Medical, leading the product mapping strategy and execution for a breakthrough surgical sealant and adhesive technology culminating in a $370 million acquisition and integration into Johnson & Johnson where Jim then served as VP of strategy within the biologicals division.
Previous to Closure Medical/J&J, Jim held several positions of increasingly greater responsibility in strategic and product marketing and corporate development over eleven years at cardiac medical device leader St. Jude Medical (now Abbott). Jim holds a master of management from Northwestern University’s Kellogg Graduate School of management and a bachelor’s degree from Indiana University. Jim resides with his wife Lisa and four children in Orono, Minnesota, USA
This person is not in any offices
Clear-Cut Medical
Clear-Cut Medical is a medical device company based in Rehovot, Israel with a US subsidiary in Minneapolis, Minnesota that is dedicated to improving the quality of care for cancer patients through its novel intra-operative MRI technology. The company has developed the compact, mobile, affordable and easy to use ClearSight™ system for excised tissue assessment. The system utilizes state of the art proprietary MRI technology for real time tissue margin assessment. Clinical trial results of the ClearSight™ system in breast conserving surgery have shown high sensitivity and specificity and it will be commercialized with the objective of significantly reducing the need for repeat surgery in Lumpectomy patients.